TapewireFind a company

person · Reporting owner

Robb Gary Charles

Disclosed activity across 1 company

Tapewire entity
2634
SEC CIK
0001529655

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
CORCEPT THERAPEUTICS INCCORT · Entity 2620Chief Business OfficerSeptember 24, 2026September 28, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CORCEPT THERAPEUTICS INC

Report date September 24, 2026 · Filed September 28, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect14,056 Reported balance After 2026-09-24 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-09-24 · Gift · Disposed 17,100 · Balance 14,056

F1: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 164 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Common StockSEC Table I · non-derivativeIndirectCustodial Account for Child20,571 Reported balance After 2026-09-24 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2026-09-24 · Gift · Acquired 5,000 · Balance 20,571

F2: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

Common StockSEC Table I · non-derivativeIndirectCustodial Account for Child20,571 Reported balance After 2026-09-24 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2026-09-24 · Gift · Acquired 5,000 · Balance 20,571

F3: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

Common StockSEC Table I · non-derivativeIndirectGary Charles Robb TTE Robb Revocable Trust39,716 Reported balance Holding disclosure · report date 2026-09-24 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 39,716

F4: These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 499 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026, 776 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026 and 164 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

F2: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

F3: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

F4: These shares are held by Gary Charles Robb TTE Robb Revocable Trust of which the Reporting Person is trustee.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 13, 2023 Filed Dec 16, 2023 02:31 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 OtherCommon Stock 1,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-070903 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Custodial Account for Child

Disclosed balance after: 7,700

F1 · kind: These shares were transferred from the custodial account to the child's personal account.

F2 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

Read SEC document
December 08, 2023 Filed Dec 13, 2023 01:46 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 639 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-069849 · ownership.xml · nonDerivative · entry 3

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Custodial Account for Child

Disclosed balance after: 8,700

F1 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

Read SEC document
December 08, 2023 Filed Dec 13, 2023 01:46 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 639 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-069849 · ownership.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Custodial Account for Child

Disclosed balance after: 8,700

F1 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

Read SEC document
December 08, 2023 Filed Dec 13, 2023 01:46 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 639 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-069849 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Custodial Account for Child

Disclosed balance after: 8,700

F1 · ownership.nature: These shares are held by a child of the Reporting Person through a custodial account under the Uniform Transfers to Minors Act for which the Reporting Person is custodian.

Read SEC document
December 06, 2023 Filed Dec 7, 2023 01:56 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 6,212 $27.01 $167,786.12
Disclosure

SEC source: 0000950170-23-068650 · ownership.xml · nonDerivative · entry 4

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,390

F1 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
December 05, 2023 Filed Dec 7, 2023 01:56 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 1,381 $26.27 $36,277.21
Disclosure

SEC source: 0000950170-23-068650 · ownership.xml · nonDerivative · entry 3

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,602

F1 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
December 04, 2023 Filed Dec 7, 2023 01:56 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Exercise / conversionStock option (right to buy) · Derivative 15,000 $0.00 Strike: $3.29 $0.00
Disclosure

SEC source: 0000950170-23-068650 · ownership.xml · derivative · entry 8

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,037

Underlying: Common Stock · 15,000 shares

Expires 2025-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully exercisable.

Read SEC document
December 04, 2023 Filed Dec 7, 2023 01:56 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Tax withholdingCommon Stock 8,788 $26.26 $230,772.88
Disclosure

SEC source: 0000950170-23-068650 · ownership.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,983

F2 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on December 4, 2023. The options subject to the net exercise were to expire on February 18, 2025.

F1 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
December 04, 2023 Filed Dec 7, 2023 01:56 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Exercise / conversionCommon Stock 15,000 $3.29 $49,350.00
Disclosure

SEC source: 0000950170-23-068650 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,771

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
December 01, 2023 Filed Dec 5, 2023 23:23 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GrantCommon Stock 638 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-068330 · ownership.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,771

F5 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

F4 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
December 01, 2023 Filed Dec 5, 2023 23:23 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GrantCommon Stock 638 $25.97 $16,568.86
Disclosure

SEC source: 0000950170-23-068330 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,133

F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on December 1, 2023.

F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

F3 · balance_after: A Form 4 previously filed on September 6, 2023 inadvertently overstated the number of shares held by 501. The number in Column 5 reflects the corrected amount. This error was carried forward in the subsequent Form 4s which were filed on September 18, 2023 and September 20, 2023.

F4 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
September 19, 2023 Filed Sep 20, 2023 22:06 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 5,000 $32.74 $163,677.00
Disclosure

SEC source: 0000950170-23-049039 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,996

F1 · price: Represents the weighted average sale price for entire number of shares sold. The actual sale prices range from $32.72 to $32.79. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

F2 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
September 14, 2023 Filed Sep 18, 2023 22:12 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Exercise / conversionStock option (right to buy) · Derivative 13,963 $0.00 Strike: $3.29 $0.00
Disclosure

SEC source: 0000950170-23-048629 · ownership.xml · derivative · entry 6

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 13,963 shares

Expires 2025-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully exercisable.

Read SEC document
September 14, 2023 Filed Sep 18, 2023 22:12 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Tax withholdingCommon Stock 7,996 $33.80 $270,264.80
Disclosure

SEC source: 0000950170-23-048629 · ownership.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,996

F2 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on September 14, 2023. The options subject to the net exercise were to expire on February 18, 2025.

F1 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
September 14, 2023 Filed Sep 18, 2023 22:12 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Exercise / conversionCommon Stock 13,963 $3.29 $45,938.27
Disclosure

SEC source: 0000950170-23-048629 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 34,992

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
September 01, 2023 Filed Sep 6, 2023 22:15 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GrantCommon Stock 500 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-046811 · ownership.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,029

F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
September 01, 2023 Filed Sep 6, 2023 22:15 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GrantCommon Stock 500 $33.10 $16,550.00
Disclosure

SEC source: 0000950170-23-046811 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,529

F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2023.

F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 13, 2023 Filed Jun 16, 2023 10:10 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 600 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-028453 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,029

F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 08, 2023 Filed Jun 13, 2023 01:15 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 725 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-027554 · ownership.xml · nonDerivative · entry 8

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Custodial Account for Child

Disclosed balance after: 8,061

F2 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian.

Read SEC document
June 08, 2023 Filed Jun 13, 2023 01:15 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 725 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-027554 · ownership.xml · nonDerivative · entry 7

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Custodial Account for Child

Disclosed balance after: 8,061

F2 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian.

Read SEC document
June 08, 2023 Filed Jun 13, 2023 01:15 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 725 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-027554 · ownership.xml · nonDerivative · entry 6

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · Custodial Account for Child

Disclosed balance after: 8,061

F2 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian.

Read SEC document
June 08, 2023 Filed Jun 13, 2023 01:15 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 650 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-027554 · ownership.xml · nonDerivative · entry 5

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,629

F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 08, 2023 Filed Jun 13, 2023 01:15 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 725 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-027554 · ownership.xml · nonDerivative · entry 4

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 21,279

F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 08, 2023 Filed Jun 13, 2023 01:15 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 725 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-027554 · ownership.xml · nonDerivative · entry 3

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,004

F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 08, 2023 Filed Jun 13, 2023 01:15 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 725 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-027554 · ownership.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,729

F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 08, 2023 Filed Jun 13, 2023 01:15 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 725 $0.00 $0.00
Disclosure

SEC source: 0000950170-23-027554 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,454

F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, and 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 01, 2023 Filed Jun 5, 2023 23:04 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GrantCommon Stock 2,091 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-014516 · doc4.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,179

F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
June 01, 2023 Filed Jun 5, 2023 23:04 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GrantCommon Stock 2,091 $22.97 $48,030.27
Disclosure

SEC source: 0000899243-23-014516 · doc4.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,088

F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on June 1, 2023.

F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
May 10, 2023 Filed May 11, 2023 23:30 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 14,000 $24.07 $336,980.00
Disclosure

SEC source: 0000899243-23-012758 · doc4.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,997

F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $23.99 to $24.16. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
May 09, 2023 Filed May 11, 2023 23:30 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 30,000 $23.87 $716,100.00
Disclosure

SEC source: 0000899243-23-012758 · doc4.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,997

F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $23.81 to $24.04. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
May 05, 2023 Filed May 9, 2023 20:45 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Exercise / conversionStock option (right to buy) · Derivative 60,000 $0.00 Strike: $3.29 $0.00
Disclosure

SEC source: 0000899243-23-012473 · doc4.xml · derivative · entry 8

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,963

Underlying: Common Stock · 60,000 shares

Expires 2025-02-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully exercisable.

Read SEC document
May 05, 2023 Filed May 9, 2023 20:45 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Exercise / conversionStock option (right to buy) · Derivative 45,000 $0.00 Strike: $1.92 $0.00
Disclosure

SEC source: 0000899243-23-012473 · doc4.xml · derivative · entry 7

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 45,000 shares

Expires 2023-11-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully exercisable.

Read SEC document
May 05, 2023 Filed May 9, 2023 20:45 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Tax withholdingCommon Stock 60,586 $24.07 $1,458,305.02
Disclosure

SEC source: 0000899243-23-012473 · doc4.xml · nonDerivative · entry 3

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 63,997

F1 · kind: These shares were withheld so the Reporting Person could satisfy the exercise price and tax liability arising from a net (cashless) exercise of stock options that occurred on May 5, 2023.

F2 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
May 05, 2023 Filed May 9, 2023 20:45 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Exercise / conversionCommon Stock 60,000 $3.29 $197,400.00
Disclosure

SEC source: 0000899243-23-012473 · doc4.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 124,583

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
May 05, 2023 Filed May 9, 2023 20:45 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 Exercise / conversionCommon Stock 45,000 $1.92 $86,400.00
Disclosure

SEC source: 0000899243-23-012473 · doc4.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,583

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022, and 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 23:53 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GrantCommon Stock 1,600 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-007053 · doc4.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,583

F4 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 23:53 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GrantCommon Stock 1,600 $19.86 $31,776.00
Disclosure

SEC source: 0000899243-23-007053 · doc4.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,983

F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on March 1, 2023.

F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

F3 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
February 22, 2023 Filed Feb 13, 2024 01:12 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 1,175 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-014085 · ownership.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,465

F1 · balance_after: Includes 1,600 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 1, 2023, 2,091 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2023, and 500 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2023. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
February 13, 2023 Filed Feb 16, 2023 00:59 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GrantStock option (right to buy) · Derivative 200,000 $0.00 Strike: $23.06 $0.00
Disclosure

SEC source: 0000950170-23-002950 · ownership.xml · derivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 200,000

Underlying: Common Stock · 200,000 shares

Expires 2033-02-12

F1 · derivative.exercise_date: Exercisable ratably in equal installments on each monthly anniversary of February 13, 2023 over a four-year period.

Read SEC document
December 15, 2022 Filed Feb 15, 2023 00:30 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 772 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-005068 · doc5.xml · nonDerivative · entry 11

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Custodial account for child

Disclosed balance after: 7,336

F1 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian.

Read SEC document
December 15, 2022 Filed Feb 15, 2023 00:30 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 772 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-005068 · doc5.xml · nonDerivative · entry 10

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Custodial account for child

Disclosed balance after: 7,336

F1 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian.

Read SEC document
December 15, 2022 Filed Feb 15, 2023 00:30 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 772 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-005068 · doc5.xml · nonDerivative · entry 9

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · Custodial account for child

Disclosed balance after: 7,336

F1 · ownership.nature: These shares are held by a child of the reporting person through a custodial account under the Uniform Transfers to Minors Act for which the reporting person is custodian.

Read SEC document
November 23, 2022 Filed Nov 23, 2022 23:30 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 186 $26.03 $4,841.58
Disclosure

SEC source: 0000899243-22-036970 · doc4.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,143

F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
November 22, 2022 Filed Nov 23, 2022 23:30 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 4,814 $26.03 $125,308.42
Disclosure

SEC source: 0000899243-22-036970 · doc4.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,329

F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
November 21, 2022 Filed Feb 15, 2023 00:30 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GiftCommon Stock 560 $0.00 $0.00
Disclosure

SEC source: 0000899243-23-005068 · doc5.xml · nonDerivative · entry 8

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,383

Read SEC document
November 18, 2022 Filed Nov 21, 2022 22:15 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 13,401 $26.43 $354,188.43
Disclosure

SEC source: 0000899243-22-036534 · doc4.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,143

F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
November 17, 2022 Filed Nov 21, 2022 22:15 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 10,000 $26.06 $260,600.00
Disclosure

SEC source: 0000899243-22-036534 · doc4.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,544

F1 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
September 07, 2022 Filed Sep 8, 2022 21:15 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 SaleCommon Stock 50,000 $26.06 $1,303,000.00
Disclosure

SEC source: 0000899243-22-030683 · doc4.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,544

F1 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $25.72 to $26.39. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

F2 · balance_after: Includes 1,010 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 1, 2022. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

Read SEC document
September 01, 2022 Filed Sep 7, 2022 00:59 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GrantCommon Stock 1,010 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-030517 · doc4.xml · nonDerivative · entry 2

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 99,544

F3 · shares: Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements under the Purchase Plan.

Read SEC document
September 01, 2022 Filed Sep 7, 2022 00:59 UTC CORCEPT THERAPEUTICS INC CORT · Entity 2620 GrantCommon Stock 1,010 $25.98 $26,239.80
Disclosure

SEC source: 0000899243-22-030517 · doc4.xml · nonDerivative · entry 1

Robb Gary Charles · CIK 0001529655 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,534

F1 · shares: The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2022.

F2 · price: In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.